{"version":"1.0","type":"link","title":"Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.","author_name":"Peng N 외","author_url":"https://prs-insight.online/author/Peng%20N","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/119599","thumbnail_width":1200,"thumbnail_height":630}